A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

Pauli C., Bochtler T., Mileshkin L., Baciarello G., Losa F., Ross J. S., ...More

ONCOLOGIST, vol.26, no.5, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 5
  • Publication Date: 2021
  • Doi Number: 10.1002/onco.13744
  • Journal Name: ONCOLOGIST
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Keywords: Cancer of unknown primary, Diagnosis, Histology, Molecularly guided therapy, Comprehensive genomic profiling, Next&#8208, generation sequencing, PRIMARY SITE, BOSNIAK CLASSIFICATION, DIAGNOSIS, EXPRESSION, CARCINOMA, ORIGIN, NEOPLASMS, SPREAD
  • Hacettepe University Affiliated: Yes


Background CUPISCO is an ongoing randomized phase II trial (NCT03498521) comparing molecularly guided therapy versus platinum-based chemotherapy in patients newly diagnosed with "unfavorable" cancer of unknown primary (CUP).